Q BioMed

Accelerating Biomedical Technologies from Incubation to Monetization

366 Madison Avenue, 3rd Floor | New York, NY 10017 | +1 646 889 2226 | **www.qbiomed.com**

Company Overview

Q BioMed (QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed launched its FDA approved, non-opioid drug Strontium89 (strontium chloride Sr-89 Injection, USP), which relieves pain from metastatic cancer in the bone, in the U.S. in February 2020. Strontium89 is Medicare/payor reimbursed in the U.S. and is available outside the U.S. to a potential global population of 10 million people through a Named Patient Program. Q BioMed's clinical pipeline in oncology, vascular disease, and rare orphan diseases addresses unmet medical needs in large markets and is expected to produce substantial revenues for the Company and value inflection points for investors for years to come.

Q BioMed

Equity Overview

(as of February 3, 2021)

Ticker: QBIO
Stock Price: $1.10
Shares Outstanding: 24 M
Market Cap: $26 M
Avg. Trading Volume (90 day): 104,000
Inside Ownership: 25%

Covid-19 Clinical Trial expected Q3 2021

strontium89
Strontium Chloride Sr-89
Injection, USP

Commercialized Product:
Non-Opioid Pain Relief for Cancer Patients Whose Cancer Has Metastasized to Bones

$25 M - $50 M Annual Revenue Potential

- FDA approved to treat bone pain from cancer metastases
- Medicare reimbursed in U.S.
- Launched in U.S. Q1 2020
- US and global revenue growth expected in 2021
- Global distribution through Named Patient Program announced July 2020
- International market approval expected mid 2021

$250 M - $500 M Annual Revenue Potential (after completion of additional study)

- Potential to treat metastatic bone cancer
- Clinical trials planned for Q4 2021 to support label extension and cancer survival benefit
- Competing product generates $800 M/year

Q BioMed

Accelerating Biomedical Technologies from Incubation to Monetization

366 Madison Avenue, 3rd Floor | New York, NY 10017 | +1 646 889 2226 | **www.qbiomed.com**

Investment Highlights



Launched FDA Approved Drug for Non-Opioid Pain Relief

Strontium89 is an FDA approved, non-opioid drug that relieves the severe pain associated with cancer that has metastasized to bone, a condition that impacts an estimated 10 million people. Strontium89 has been shown to relieve pain in over 75% of patients who received the treatment. Q BioMed is hopeful that broad market acceptance will be swift. Strontium89 is reimbursed by Medicare and most private payers, and is anticipated to generate revenues of $25 to $50 million annually in the next 3 years. The drug is now available globally through a Named Patient Program.

Label Extension Trial for Strontium89 in Treatment of Metastatic Bone Cancer

Based on data published in The Lancet showing Strontium89 extends overall survival, Q BioMed is planning an additional clinical trial for Strontium89 to support a label extension from the current pain palliation into therapeutic use for survival benefit in metastatic bone cancer. This new indication has the potential to generate significant revenues annually. A comparative drug in this therapeutic space was purchased by Bayer for $2.9 billion in 2013, with peak sales projected by Bayer to exceed $1 billion a year.

QBM-001 for Pediatric Non-verbal Autism Disorder

In a breakthrough, Q BioMed discovered the first two biomarkers for pediatric nonverbal autism, a condition which impacts 18,000 children in the U.S. and 40,000 worldwide. An application for Orphan Drug Designation has been filed with the FDA.

Uttroside-B Shown to be 10-X More Potent Against Liver Cancer Cells

Q BioMed's Uttroside-B, which received FDA Orphan Drug Designation, may be up to 10 times more potent against liver cancer cells than Sorafenib (based on preclinical data), the leading FDA approved drug for first line treatment of liver cancer. The Company is now scaling up production of the drug in anticipation of commencing proof of concept studies in H2 2021 and filing an IND with the FDA in 2022.

Mannin Platform for COVID-19, Kidney Disease & Glaucoma

Q BioMed's research partner, Mannin Research Inc., was granted up to $7.5 million from the German state of Saxony to advance its preclinical pipeline which includes drug candidates optioned to Q BioMed including Man-19. An IND filing is expected for Man-19 for the treatment of COVID-19 in Q2 2021, with a clinical trial anticipated Q3 2021. Man-01 for the topical treatment of glaucoma is also expected to commence a clinical trial in 2021.